|Description||Elafibranor is a dual PPARα/δ agonist. Elafibranor increases plasma HDL and expression of Acox1, a PPARα target gene, and decreases plasma triglycerides and total cholesterol in the liver of ApoE2-KI wild-type mice. Elafibranor is identified as a drug candidate for the treatment of cardiometabolic diseases such as diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).|
|B0084-074234||250 mg||$299||In stock|
|Brife Description||PPARα/δ agonist|
|Synonyms||Elafibranor; GFT505; GFT-505; GFT 505; 2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid|
|Application||potential treatment of cardiometabolic diseases|
Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used for the treatment of hyperlipidaemia. It helps to lower LDL cholesterol a...
GW-9820 is a PPAR-gamma agonist with potential antidiabetic effect.
Oleylethanolamide is an endogenous agonist for PPARα with an EC50 value of 120 nM in a transactivation assay. Oleylethanolamide is also a selective GPR55 agonis...
Lanifibranor is a peroxisome proliferator-activated receptors (PPAR) agonist.
KRP297, also called as L4 10198 or MK 767, is a Peroxisome proliferator-activated receptor (PPAR) alpha and gamma (PPARα and PPARγ) agonist. With potential to t...
A potent PPARα modulator
The Rs for the separations were 3.5 for balaglitazone enantiomers, 3.5 for pioglitazone enantiomers, and 3.7 for rosiglitazone. The squared correlation coeffici...
CS-7017 monohydrate is a peroxisome proliferator activated receptor gamma (PPAR) agonist. It is a potential therapy for thyroid cancer and liposarcoma. It is al...